First-in-class small molecule eliminates cccDNA in the hepatitis B virus (HBV)-infected liver
ILC 2019: Orally-administered small molecule, ccc_R08, eliminates covalently closed circular DNA (cccDNA) in the liver of an HBV cccDNA mouse model: a step towards a sterilizing cure? 12 April 2019,…
Faecal microbiota capsules effective and well tolerated in individuals with recurrent hepatic encephalopathy
ILC 2019: Oral faecal microbiota capsules reduce hospitalizations, improve duodenal microbial diversity, and enhance cognitive function when added to standard-of-care in individuals with cirrhosis and recurrent hepatic encephalopathy 12 April…
HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease
ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
Autoimmune diseases of the liver may be partly triggered by exposure to an environmental factor
ILC 2019: UK disease clustering study suggests that environmental exposure may play a key role in the development of some autoimmune liver diseases 11 April 2019, Vienna, Austria EASL (EUROPEAN…
Homelessness may be a barrier to success for hepatitis C ‘Treatment as Prevention’ programmes
ILC 2019: ‘Treatment as Prevention’ programme for hepatitis C in Iceland reports high levels of cure, but homelessness is found to be a barrier to success 11 April 2019, Vienna,…